$1,318.00
This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
8 Risk factors
9 Diagnosis
9 Patient segmentation
10 TREATMENT
10 Anticoagulants
10 Thrombolytic therapy
11 Inferior vena cava filter
11 Thrombectomy/embolectomy
12 EPIDEMIOLOGY
19 MARKETED DRUGS
24 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Milvexian for VTE (November 15, 2021)
31 MAA868 for VTE (July 19, 2021)
34 KEY REGULATORY EVENTS
34 British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare
34 Mylan’s Two Generic Nods Include Xarelto Rival
34 Activity In Pediatric Anticoagulation: Pradaxa Approved, Xarelto Submitted
36 PROBABILITY OF SUCCESS
37 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
42 Recent events
43 BIBLIOGRAPHY
44 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of DVT, 2020–29
18 Figure 2: Trends in incident cases of PE, 2020–29
24 Figure 3: Overview of pipeline drugs for VTE in the US
24 Figure 4: Pipeline drugs for VTE, by company
25 Figure 5: Pipeline drugs for VTE, by drug type
25 Figure 6: Pipeline drugs for VTE, by classification
31 Figure 7: Milvexian for VTE (November 15, 2021): Phase II – AXIOMATIC-TKR
33 Figure 8: MAA868 for VTE (July 19, 2021): Phase II – ANT-005
36 Figure 9: Probability of success in the VTE pipeline
39 Figure 10: Clinical trials in VTE
39 Figure 11: Top 10 drugs for clinical trials in VTE
40 Figure 12: Top 10 companies for clinical trials in VTE
40 Figure 13: Trial locations in VTE
41 Figure 14: VTE trials status
42 Figure 15: VTE trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of DVT, 2020–29
16 Table 2: Incident cases of PE, 2020–29
20 Table 3: Marketed drugs for VTE
26 Table 4: Pipeline drugs for VTE in the US
29 Table 5: Milvexian for VTE (November 15, 2021)
31 Table 6: MAA868 for VTE (July 19, 2021)
37 Table 7: Historical global sales, by drug ($m), 2017–21
38 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!